Objective: To observe the clinical effect of gleevec on Ph+ acute lymphoblastic leukaemia ( Ph+ ALL ) cases in children.Methods:9 cases of children Ph+ALL were retrospectively analyzed.All of the data were obtained from department of hematol-ogy/oncology, in our hospital from January 2011 to May 2014.All the patients were treated with 340 mg/m2・d of oral gleevec in 0.5 h af-ter meals, 30d for a course of treatment meanwhile, observed the genetics remission rate and recorded the occurrence of side effects trea-ted with gleevec.Results:9 cases(100%) were achieved complete genetic remission.With median follow-up time for 18 months, 9 ca-ses of survival rate of Ph+ALL patients was 67%in 2~4 years.Of the patients, 2 cases of recurrence after 13 months gave up treat-ment.1 case was treated for allogeneic hematopoietic stem cell transplantation after recurrence.Different levels of hypocytosis occured after 16 weeks (medium time was approximately 3~4 weeks).Including animia 7 cases(78%), thrombocytopenia 5 cases(56%), leukocyto-penia 6 cases(67%), pancytopenia 3 cases(33%).Nausea and vomiting occurred in 4 cases(44%) and muscle pain occurred in 2 ca-ses(22%) which returned to normal after discontinuation or reduction.Conclusion:Gleevec is both effective and safe for the treatment of Ph+ALL.%目的：评价格列卫治疗儿童Ph染色体阳性急性淋巴细胞白血病Ph＋（ acute lymphoblastic leukaemia，Ph＋ALL）的效果和不良反应。方法：收集我院血液肿瘤科2011年1月至2013年5月确诊的9例Ph＋ALL患儿，于诱导治疗后开始口服格列卫340 mg／m2・d，30 d为1疗程，每次于饭后0.5 h口服，观察格列卫治疗后Ph＋ALL患者遗传学缓解率，并记录不良反应。结果：9例患儿口服格列卫后均达到遗传学缓解，缓解率100％（9／9），随访2～4年，中位数时间18个月时的总生存率67％。其中2例于治疗后13个月复发放弃治疗，1例于治疗后6个月复发行异基因造血干细胞移植术。患者在服药后16周（中位时间约3～4周）出现不同程度的血细胞减少。其中7例（78％）出现贫血，5例（56％）出现血小板减少，6例（67％）出现白细胞减少，3例（33％）为全血细胞减少，4例（44％）出现恶心、呕吐胃肠道反应，2例（22％）有肌肉疼痛，予以减量或停药后均可恢复正常。结论：格列卫治疗儿童Ph＋ALL不仅有效而且安全。
展开▼
